Mesoblast (MEOBF) Stock Price, Quote, News & History

Mesoblast Ltd (MEOBF) Stock Price, Quote, News & History

MEOBFOTCPK

Trade with Public

Price data is not available

Key Statistics

Open

Volume / Avg.

2.32M / 705.00

Day Range

- - -

52 Wk Range

0.96 - 2.59

Market Cap

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

35.49

Recent Mesoblast Ltd News

MindMed Appoints Schond L. Greenway As CFO

Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.

Vuk Zdinjak

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

Investing Cash Flow (TTM)

-1.11M

Financing Cash Flow (TTM)

150.47M

Free Cash Flow (TTM)

-60.75M

Capital Expenditure (TTM)

-1.11M

Net Change in Cash (TTM)

89.72M

Valuation Metrics

Enterprise Value

$1.86B

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

31.39

PB Ratio (TTM)

3.59

Earnings Yield % (TTM)

-4.61%

Earnings Yield % (FWD)

-0.28%

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$0.45

Company Debt

Total Debt

$126.87M

LT Debt

$60.13M

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$76.66M

Total Cash

$129.57M

Debt to Equity

0.24

Issuance of Debt (TTM)

-$5.31M

Repayment of Debt (TTM)

-$76.66M

Key Statistics

Open

Volume / Avg.

2.32M / 705.00

Day Range

- - -

52 Wk Range

0.96 - 2.59

Market Cap

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

35.49

About

Sector

Health Care

Industry

Biotechnology

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates includ...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

How do I buy Mesoblast (MEOBF) stock?

You can purchase shares of Mesoblast (OTCPK:MEOBF) through any online brokerage.

View our list of the best stock brokerages

Who are Mesoblast (MEOBF) competitors?

There are no as such competitors for Mesoblast.

What is the forecast, or price target, for Mesoblast (MEOBF) stock?

There is no analysis for Mesoblast to provide a consensus price target.

What is the current price for Mesoblast (MEOBF)?

The stock price for Mesoblast (OTCPK: MEOBF) is $ last updated .

Does Mesoblast (MEOBF) pay a dividend?

There are no upcoming dividends for Mesoblast.

When is Mesoblast (OTCPK:MEOBF) reporting earnings?

Mesoblast does not have any upcoming earnings scheduled.

Is Mesoblast (MEOBF) going to split?

There is no upcoming split for Mesoblast.

What sector and industry does Mesoblast (MEOBF) operate in?

Mesoblast is in the Health Care sector and Biotechnology industry. They are listed on the OTCPK.

Key Statistics

Open

Volume / Avg.

2.32M / 705.00

Day Range

- - -

52 Wk Range

0.96 - 2.59

Market Cap

P/E Ratio

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

35.49

Recent Mesoblast Ltd News

MindMed Appoints Schond L. Greenway As CFO

Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.

Vuk Zdinjak